International audienceObjectives: The diffusion of the SARS-CoV-2 Delta (B.1.617.2) variant and the waning of immune response after primary Covid-19 vaccination favoured the breakthrough SARS-CoV-2 infections in vaccinated subjects. To assess the impact of vaccination, we determined the severity of infection in hospitalised patients according to vaccine status. Methods: We performed a retrospective observational study on patients hospitalised in 10 centres with a SARS-CoV-2 infection (Delta variant) from July to November 2021 by including all patients who had completed their primary vaccination at least 14 days before hospital admission and the same number of completely unvaccinated patients. We assessed the impact of vaccination and other ...
Background: Concerns have been raised regarding the risks of SARS-CoV-2 breakthrough infections in v...
Background: The SARS-CoV-2 delta (B.1.617.2) variant was first detected in England in March, 2021. I...
(1) Background: Some COVID-19 vaccine recipients show breakthrough infection. It remains unknown, wh...
International audienceObjectives: The diffusion of the SARS-CoV-2 Delta (B.1.617.2) variant and the ...
Vaccine breakthrough SARS-CoV-2 infections necessitating hospitalization have emerged as a relevant ...
Vaccine breakthrough SARS-CoV-2 infections necessitating hospitalization have emerged as a relevant ...
International audienceObjectives: The emergence of SARS-CoV-2 variants raised questions about the ex...
International audienceBackgroundWe aimed to assess the settings and activities associated with SARS-...
Funder: Medical Research CouncilFunder: Wellcome TrustBackgroundThe SARS-CoV-2 delta (B.1.617.2) var...
Waning humoral immunity after mRNA vaccination against severe acute respiratory syndrome coronavirus...
Background: The SARS-CoV-2 delta (B.1.617.2) variant was first detected in England in March, 2021. I...
Background: Breakthrough infections after SARS-CoV-2 infection have been reported. Clinical outcomes...
Background: Concerns have been raised regarding the risks of SARS-CoV-2 breakthrough infections in v...
Background: The SARS-CoV-2 delta (B.1.617.2) variant was first detected in England in March, 2021. I...
(1) Background: Some COVID-19 vaccine recipients show breakthrough infection. It remains unknown, wh...
International audienceObjectives: The diffusion of the SARS-CoV-2 Delta (B.1.617.2) variant and the ...
Vaccine breakthrough SARS-CoV-2 infections necessitating hospitalization have emerged as a relevant ...
Vaccine breakthrough SARS-CoV-2 infections necessitating hospitalization have emerged as a relevant ...
International audienceObjectives: The emergence of SARS-CoV-2 variants raised questions about the ex...
International audienceBackgroundWe aimed to assess the settings and activities associated with SARS-...
Funder: Medical Research CouncilFunder: Wellcome TrustBackgroundThe SARS-CoV-2 delta (B.1.617.2) var...
Waning humoral immunity after mRNA vaccination against severe acute respiratory syndrome coronavirus...
Background: The SARS-CoV-2 delta (B.1.617.2) variant was first detected in England in March, 2021. I...
Background: Breakthrough infections after SARS-CoV-2 infection have been reported. Clinical outcomes...
Background: Concerns have been raised regarding the risks of SARS-CoV-2 breakthrough infections in v...
Background: The SARS-CoV-2 delta (B.1.617.2) variant was first detected in England in March, 2021. I...
(1) Background: Some COVID-19 vaccine recipients show breakthrough infection. It remains unknown, wh...